news
UK-US post-Brexit trade deal risks increased drug prices
A trade deal between the UK and USA could risk increasing drug prices in the UK, which could diminish the affordability and accessibility of the NHS...
List view / Grid view
Drug Markets
news
FDA approves first biosimilar to Neulasta
The U.S. Food and Drug Administration has approved Fulphila (pegfilgrastim-jmdb) as the first biosimilar to Neulasta to help reduce the risk of infection during cancer treatment.
news
New cancer immunotherapy drugs rapidly reach patients after approval
The majority of patients eligible for cancer immunotherapy drugs known as checkpoint inhibitors received treatment within a few months of FDA approval, according to a new Yale-led study.
news
FDA approves Lutathera for somatostatin receptor-positive GEP-NETs
The FDA has approved Lutathera for the treatment of a type of cancer that affects the pancreas the gastrointestinal tract...
news
EMA grants marketing authorisation for Zubsolv for opioid dependence
The EMA has granted a Marketing Authorization for Zubsolv, a novel rapidly-disintegrating treatment option for opioid dependence...
news
FDA approves Mylotarg for treatment of acute myeloid leukemia
The FDA has approved Mylotarg for the treatment of adults with newly diagnosed acute myeloid leukaemia whose tumours express the CD33 antigen...
news
Novartis receives EU approval for ribociclib
Novartis announced that the European Commission approved ribociclib in combination with an aromatase inhibitor for treatment of postmenopausal women with metastatic breast cancer
news
FDA grants approval of Besponsa for acute lymphoblastic leukaemia
The FDA has approved Besponsa for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia...
news
C difficile infections market to hit $1.7bn by 2026
GlobalData latest report states that the major drivers of this growth include the projected launch of prophylactic options for the prevention of Clostridium difficile infections...
news
Heart failure market worth $16 billion by 2026 as Novartis’ drug triggers growth
The heart failure space across the seven key markets of the US, France, Germany, Italy, Spain, the UK and Japan is set to grow from $3.7 billion in 2016 to around $16.1 billion by 2026, representing an impressive compound annual growth rate of 15.7%, according to research and consulting firm…
article
2017 pipelines: Analysing future trends in the $12billion diabetes market
3 April 2017 | By Dr David Pugh, IDTechEx
The latest 2017 pipelines explores new emerging methods of glucose monitoring, analysing these technologies in the new report from IDTechEx Research...
article
P is for Psoriasis
5 December 2016 | By Niamh Louise Marriott, Digital Editor
P is for Psoriasis - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
article
M is for MRSA
30 November 2016 | By Niamh Louise Marriott, Digital Editor
M is for MRSA - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest research...
article
I is for Immuno-oncology
24 November 2016 | By Niamh Louise Marriott, Digital Content Producer
I is for Immuno-oncology - the next instalment of our daily pharmaceutical alphabet bringing you up to date with all the latest in this cancer research...
news
ADHD market predicted to reach $13.9 billion by 2024
8 September 2016 | By Niamh Louise Marriott, Digital Content Producer
The market for attention deficit hyperactivity disorder (ADHD) across the seven major markets (7MM) of the US, France, Germany, Italy, Spain, the UK, and Japan, is set to experience an increase from approximately $6.1 billion in 2014 to $13.9 billion by 2024, at a compound annual growth rate of 8.5%,…
